All patients (N = 1937) | |
---|---|
Age (years) - median (range) | 56 (23–97) |
Marital status - N (%) | |
Not partnered | 411 (21.3) |
Partnered | 651 (33.6) |
Unknown | 875 (45.1) |
Employment status - N (%) | |
Not working outside home | 609 (31.4) |
Working outside home | 900 (46.5) |
Unknown | 428 (22.1) |
BMIa (kg/m2) - N (%) | |
<20 | 292 (15.1) |
20-25 | 925 (47.8) |
26-30 | 450 (23.2) |
>30 Unknown | 221 (11.4) 49 (2.5) |
Breast size (cm) - median (range) | 90 (65–130) |
Cup size - N (%) | |
A | 108 (5.6) |
B | 521 (26.9) |
C | 299 (15.4) |
≥D | 183 (9.5) |
Unknown | 826 (42.6) |
Tobacco users - N (%) | 296 (15.3) |
ASAb score - N (%) | |
ASA 1 | 1051 (54.2) |
ASA 2 | 824 (42.6) |
ASA >2 | 62 (3.2) |
Histologic stage - N (%) | |
In situ | 335 (17.3) |
SBR c I | 217 (11.2) |
SBR II | 716 (37) |
SBR III | 614 (31.7) |
Invasive SBR unknown | 54 (2.8) |
Tumor size (cm) - N (%) | |
<2 | 603 (31.2) |
2-5 | 919 (47.5) |
>5 | 316 (16.3) |
Unknown | 98 (5) |
Estrogen receptors positive - N (%) | 1251 (64.6) |
Progesterone receptors positive - N (%) | 444 (22.9) |
Overexpression HER2 - N (%) | 228 (11.8) |
Axillary lymph nodes positive - N (%) | 726 (37.5) |
Inflammatory cancer - N (%) | 92 (4.8) |
Metastatic cancer - N (%) | 83 (4.3) |
Indication of mastectomy - N (%) | |
Clinicobiological characteristics of cancer | 1061 (54.8) |
Failure conservative surgery | 357 (18.4) |
Local recurrence | 519 (26.8) |
Chemotherapy - N (%) | |
Adjuvant | 715 (36.9) |
Neoadjuvant | 284 (14.7) |
Radiotherapy - N (%) | 971 (50.2) |
Hormone therapy - N (%) | 1175 (60.7) |